Inspira Technologies
Inspira Technologies is an innovative medical device company specializing in respiratory support technology. Their mission is to develop advanced solutions like the INSPIRA™ ART500 to provide non-invasive, awake patient treatment options that could potentially replace mechanical ventilation, aiming to improve patient outcomes and reduce hospital stays. The company's vision is to revolutionize acute respiratory care through continuous innovation, proprietary patents, and strategic global partnerships.
Industries
Nr. of Employees
small (1-50)
Inspira Technologies
Ha-Tidhar St 2, Ra'anana, Israel
Patents
Products
Extracorporeal blood oxygenation system (Gen 1) — short-duration perfusion
A low-flow extracorporeal device configuration intended to pump blood during short-duration cardiopulmonary bypass procedures (cleared for up to 6 hours under a regulatory 510(k) reference).
Adaptive extracorporeal oxygenation system with continuous monitoring (Gen 2)
An adaptive blood oxygenation system designed to enrich blood oxygen and remove CO2 at low flow while continuously monitoring blood parameters and providing clinician decision-assistance data (in development/preclinical and clinical evaluation).
Clip-on optical blood gas sensor (continuous blood lab)
A clip-on optical sensor designed to analyze blood gases continuously without repeated blood draws; described as under clinical evaluation with planned regulatory submission.
Convertible dual-lumen intravascular cannula
A cannula designed to be inserted as a single lumen and converted intravascularly to a dual-lumen configuration to support extracorporeal circulation with reduced insertion-related risk.
Extracorporeal blood oxygenation system (Gen 1) — short-duration perfusion
A low-flow extracorporeal device configuration intended to pump blood during short-duration cardiopulmonary bypass procedures (cleared for up to 6 hours under a regulatory 510(k) reference).
Adaptive extracorporeal oxygenation system with continuous monitoring (Gen 2)
An adaptive blood oxygenation system designed to enrich blood oxygen and remove CO2 at low flow while continuously monitoring blood parameters and providing clinician decision-assistance data (in development/preclinical and clinical evaluation).
Clip-on optical blood gas sensor (continuous blood lab)
A clip-on optical sensor designed to analyze blood gases continuously without repeated blood draws; described as under clinical evaluation with planned regulatory submission.
Convertible dual-lumen intravascular cannula
A cannula designed to be inserted as a single lumen and converted intravascularly to a dual-lumen configuration to support extracorporeal circulation with reduced insertion-related risk.
Services
Design and conduct of in-house preclinical studies and laboratory testing to evaluate device performance and provide supporting data for regulatory submissions.
Collaborative development arrangements with third parties for complementary technologies such as bio-electronic infection-prevention methods and component integration.
Design and conduct of in-house preclinical studies and laboratory testing to evaluate device performance and provide supporting data for regulatory submissions.
Collaborative development arrangements with third parties for complementary technologies such as bio-electronic infection-prevention methods and component integration.
Expertise Areas
- Acute respiratory support and artificial lung technologies
- Extracorporeal oxygenation and low-flow oxygenation methods
- Continuous blood-gas monitoring
- Medical device R&D and preclinical validation
Key Technologies
- Low-flow extracorporeal blood oxygenation
- Continuous optical blood gas sensing
- Dual-lumen intravascular cannula
- Orbiting / non-membrane blood-gas exchange
News & Updates
Inspira Technologies has regained compliance with Nasdaq's minimum bid price requirement as of July 18, 2025.
Inspira has achieved key objectives in government talks, paving the way for national adoption and global scale-up of the ART100.
Inspira announced a landmark $28 million distribution deal to expand into Central America.
Joe Hayon, CFO of Inspira, presented at the Aegis Capital virtual conference on February 23, 2022.
Inspira's blood sensor technology utilizes AI for continuous, real-time blood gas analysis, potentially transforming patient monitoring and care.
Details on Inspira's pre-clinical studies demonstrating the safety and efficacy of their blood oxygenation systems.
Inspira Technologies has regained compliance with Nasdaq's minimum bid price requirement as of July 18, 2025.
Inspira has achieved key objectives in government talks, paving the way for national adoption and global scale-up of the ART100.
Inspira announced a landmark $28 million distribution deal to expand into Central America.
Joe Hayon, CFO of Inspira, presented at the Aegis Capital virtual conference on February 23, 2022.
Inspira's blood sensor technology utilizes AI for continuous, real-time blood gas analysis, potentially transforming patient monitoring and care.
Details on Inspira's pre-clinical studies demonstrating the safety and efficacy of their blood oxygenation systems.